The “Generics UK” precedent: will the ECJ find the way out of the “restriction by object” maze?
By: Quentin Colombier (Competition Forum)
In a noteworthy ruling issued on January 30th, 2020 in response to a preliminary ruling requested by the Competition Appeal Tribunal of the United Kingdom, the Court of Justice of the European Union (“the Court”) provides interesting clarifications with respect to both the notion of “restriction of competition by object” and the notion of abuse of a dominant position. Only the notion of “restriction of competition by object” will be discussed in this paper.
In order to fully understand the Court’s approach, it is necessary to keep in mind the specific facts of the case. In the 1990s, the laboratory GlaxoSmithKline(“GSK”) marketed, in the United Kingdom, an originator medicine called “Seroxat”, the active ingredient of which is paroxetine. It is a prescription-only anti-depressant medicine, belonging to the group of medicines known as selective serotonin re-uptake inhibitors (“SSRIs”).
By 1999 and 2000, the patent protecting paroxetine and the “data exclusivity” period expired, opening the possibility for generic medicines manufacturers to enter the market. At that time, however, GSKhad obtained a series of so-called “secondary” patents, including a manufacturing process patent that remained valid until 2016.
Three generic medicines manufacturers planned to enter the British market by mid-2000 by offering for sale a generic version of paroxetine. In order to put an end to the litigation, GSKentered into a settlement agreement with each of the three generic medicines manufacturers…
Featured News
FTC to Approve Exxon’s $64 Billion Deal with Pioneer Resources, Excludes
May 1, 2024 by
CPI
UK Competition Watchdog Raises Alarm Over Nvidia’s ARM Takeover
May 1, 2024 by
CPI
Sen. Klobuchar Urges Regulators to Probe Collusion in Health Care Pricing
May 1, 2024 by
CPI
Multiple States Join Tennessee’s Antitrust Lawsuit Against NCAA Over NIL Rules
May 1, 2024 by
CPI
NY AG Joins Suit Challenging NCAA’s Restrictions on Student Athlete NIL Rights
May 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI